open access

Vol 50, No 3 (2018)
Review articles
Published online: 2018-07-11
Submitted: 2017-11-16
Accepted: 2018-04-30
Get Citation

Procalcitonin in liver dysfunction — Dr Jekyll or Mr Hyde?

Ewa Woźnica, Lidia Łysenko
DOI: 10.5603/AIT.a2018.0023
·
Pubmed: 29995971
·
Anaesthesiol Intensive Ther 2018;50(3):226-229.

open access

Vol 50, No 3 (2018)
Review articles
Published online: 2018-07-11
Submitted: 2017-11-16
Accepted: 2018-04-30

Abstract

Serum procalcitonin (PCT) is a sensitive biomarker used for the diagnosis of infection and sepsis. PCT has also some toxic effects. It is not a proinflammatory stimulus, but may augment the inflammatory processes. High levels of PCT in sepsis may lead to hepatocyte necrosis and, as a result, to liver failure. The pathomechanism of the toxic effect of PCT is still unknown. The influence of liver function on PCT levels has not been studied yet. It is not sure whether the liver dysfunction affects the diagnostic and prognostic value of serum PCT levels. In patients with acute liver failure, the usefulness of PCT-level determination remains controversial. Recent studies have shown a potential diagnostic benefit of PCT as a marker of infection in chronic liver diseases. In both groups there is still no consensus on the optimal cut-off value of PCT levels in order to exclude infection. In patients with liver disease, the serum PCT levels should be interpreted with caution, taking into consideration other factors affecting the PCT threshold.

Abstract

Serum procalcitonin (PCT) is a sensitive biomarker used for the diagnosis of infection and sepsis. PCT has also some toxic effects. It is not a proinflammatory stimulus, but may augment the inflammatory processes. High levels of PCT in sepsis may lead to hepatocyte necrosis and, as a result, to liver failure. The pathomechanism of the toxic effect of PCT is still unknown. The influence of liver function on PCT levels has not been studied yet. It is not sure whether the liver dysfunction affects the diagnostic and prognostic value of serum PCT levels. In patients with acute liver failure, the usefulness of PCT-level determination remains controversial. Recent studies have shown a potential diagnostic benefit of PCT as a marker of infection in chronic liver diseases. In both groups there is still no consensus on the optimal cut-off value of PCT levels in order to exclude infection. In patients with liver disease, the serum PCT levels should be interpreted with caution, taking into consideration other factors affecting the PCT threshold.
Get Citation

Keywords

sepsis, procalcitonin, liver dysfunction, hepatocytes

Supplementary Files (1)
Prokalcytonina w niewydolności wątroby – Dr Jekyll czy Mr Hyde? strona tytułowa
Download
13KB
About this article
Title

Procalcitonin in liver dysfunction — Dr Jekyll or Mr Hyde?

Journal

Anaesthesiology Intensive Therapy

Issue

Vol 50, No 3 (2018)

Pages

226-229

Published online

2018-07-11

DOI

10.5603/AIT.a2018.0023

Pubmed

29995971

Bibliographic record

Anaesthesiol Intensive Ther 2018;50(3):226-229.

Keywords

sepsis
procalcitonin
liver dysfunction
hepatocytes

Authors

Ewa Woźnica
Lidia Łysenko

References (37)
  1. Müller B, White JC, Nylén ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001; 86(1): 396–404.
  2. Morgenthaler NG, Struck J, Chancerelle Y, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003; 35(5): 290–295.
  3. Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010; 375(9713): 463–474.
  4. Meynaar IA, Droog W, Batstra M, et al. In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011; 2011: 594645.
  5. Morgenthaler NG, Struck J, Fischer-Schulz C, et al. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab. 2002; 48(5-6): 263–270.
  6. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000; 49 Suppl 1: S57–S61.
  7. Dymicka-Piekarska V, Wasiluk A. Procalcitonin (PCT), contemporary indicator of infection and inflammation. Postępy Higieny i Medycyny Doświadczalnej. 2015; 69: 723–728.
  8. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011; 66 Suppl 2: ii33–ii40.
  9. Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014; 34(4): 263–273.
  10. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology. 2007; 45(1): 230–241.
  11. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43(3): 304–377.
  12. Kramer L, Jordan B, Druml W, et al. Austrian Epidemiologic Study on Intensive Care, ASDI Study Group. Incidence and prognosis of early hepatic dysfunction in critically ill patients--a prospective multicenter study. Crit Care Med. 2007; 35(4): 1099–1104.
  13. Nesseler N, Launey Y, Aninat C, et al. Clinical review: The liver in sepsis. Crit Care. 2012; 16(5): 235.
  14. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010; 159(2): 253–264.
  15. Egger G, Aigner R, Glasner A, et al. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammation parameters. Intensive Care Med. 2004; 30(2): 331–334.
  16. Alves-Filho JC, de Freitas A, Spiller F, et al. The role of neutrophils in severe sepsis. Shock. 2008; 30 Suppl 1: 3–9.
  17. Hoffmann G, Czechowski M, Schloesser M, et al. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002; 30(9): 2091–2095.
  18. Pincíková T, Bucová M, Slobodníková L. [Influrence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood aganist bacteria Staphylococcus aureus and Escherichia coli]. Vnitr Lek. 2005; 51(12): 1365–1370.
  19. Wiedermann FJ, Kaneider N, Egger P, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002; 30(5): 1112–1117.
  20. Bucova M, Zahorec R, Buc M. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. Eur J Immunol. 2006; 31: 87–93.
  21. Sauer M, Doß S, Ehler J, et al. Procalcitonin Impairs Liver Cell Viability and Function In Vitro: A Potential New Mechanism of Liver Dysfunction and Failure during Sepsis? Biomed Res Int. 2017; 2017: 6130725.
  22. Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. The Lancet. 2010; 376(9736): 190–201.
  23. Habior A. Ostra niewydolność wątroby. Postępy Nauk Medycznych. 2014; 27: 24–30.
  24. Sugihara T, Koda M, Okamoto T, et al. Serum Procalcitonin in Patients with Acute Liver Failure. Yonago Acta Med. 2017; 60(1): 40–46.
  25. Mallet M, Tripon S, Thabut D, et al. Elevated Levels of Procalcitonin during Acute Liver Failure are not Associated with Sepsis or Worth Outcome. Journal of Hepatology. 2016; 64(2): S308–S309.
  26. Whang KT, Vath SD, Becker KL, et al. Procalcitonin and proinflammatory cytokine in interactions in sepsis. Shock. 1999; 12(4): 268–273.
  27. Elefsiniotis IS, Skounakis M, Vezali E, et al. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol. 2006; 18(5): 525–530.
  28. Mallet M, Haq M, Tripon S, et al. Elevated procalcitonin is associated with bacterial infection during acute liver failure only when unrelated to acetaminophen intoxication. Eur J Gastroenterol Hepatol. 2017; 29(7): 811–816.
  29. Rule JA, Hynan LS, Attar N, et al. Acute Liver Failure Study Group. Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in Acute Liver Failure. PLoS One. 2015; 10(9): e0138566.
  30. Mallet M, Haq M, Tripon S, et al. Elevated procalcitonin is associated with bacterial infection during acute liver failure only when unrelated to acetaminophen intoxication. Eur J Gastroenterol Hepatol. 2017; 29(7): 811–816.
  31. Wawrzynowicz-Syczewska M. Marskość wątroby. In: Szczeklik A, Gajewski P. ed. Interna Szczeklika. Mały podręcznik . Medycyna Praktyczna, Kraków 2014/2015 : 623–627.
  32. Palma MD, Aller MA, Vara E, et al. Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rat. Cytokine. 2005; 31(3): 213–226.
  33. Wu H, Chen L, Sun Y, et al. The role of serum procalcitonin and C-reactive protein levels in predicting spontaneous bacterial peritonitis in patients with advanced liver cirrhosis. Pak J Med Sci. 2016; 32(6): 1484–1488.
  34. Cai ZH, Fan CL, Zheng JF, et al. Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis. BMC Infect Dis. 2015; 15: 55.
  35. Qu J, Feng P, Luo Y, et al. Impact of hepatic function on serum procalcitonin for the diagnosis of bacterial infections in patients with chronic liver disease: A retrospective analysis of 324 cases. Medicine (Baltimore). 2016; 95(30): e4270.
  36. Cekin Y, Cekin AH, Duman A, et al. The role of serum procalcitonin levels in predicting ascitic fluid infection in hospitalized cirrhotic and non-cirrhotic patients. Int J Med Sci. 2013; 10(10): 1367–1374.
  37. Attar BM, Moore CM, George M, et al. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. World J Gastroenterol. 2014; 20(9): 2374–2382.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl